Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination With Platinum-based Chemotherapy Versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than when treated with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin alone.


Options:
A: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): N/A
B: Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Arm Label: Single Agent Chemotherapy (Vinorelbine or Gemcitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Vinorelbine, Drug: Gemcitabine | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Atezolizumab | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): Single Agent Chemotherapy (Vinorelbine or Gemcitabine) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Single Agent Chemotherapy (Vinorelbine or Gemcitabine)
C: Arm Label: Pemetrexed/Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Bevacizumab | Arm Label: Pemetrexed/Bevacizumab/Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Bevacizumab, Drug: Carboplatin | Arm Label: Pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed, Pemetrexed/Bevacizumab, Pemetrexed/Bevacizumab/Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Pemetrexed/Bevacizumab, Pemetrexed/Bevacizumab/Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pemetrexed/Bevacizumab/Carboplatin
D: Arm Label: IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin | Arm Label: Pemetrexed + Carboplatin (AUC 6) or Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin | Arm Label: IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5) | Arm Label: Gemcitabine + Carboplatin (AUC 5) or Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5) | Intervention Type: BIOLOGICAL; Name: IMC-1121B (ramucirumab); Assigned to Arm(s): IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Carboplatin (AUC 6); Assigned to Arm(s): IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin | Intervention Type: DRUG; Name: Carboplatin (AUC 5); Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin

Answer: D